EHA 2015 | Phase 2 study of daratumumab monotherapy for heavily pretreated and refractory multiple myeloma
Jesús San Miguel
• 12 Jun 2015
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of a phase 2 trial of monotherapy with the anti-CD38 monoclonal antibody, daratumumab, in patients with multiple myeloma who have received at least three different lines of therapy or who are double refractory.
